



KING STEM CELL
HEALTHIER HAPPIER YOU

KING STEM CELL — FULL INVESTOR PPT OUTLINE

A Platform-Stage Biologics & Delivery-Tech Company



KING STEM CELL
HEALTHIER HAPPIER YOU

A Platform-Stage Biologics & Delivery-Tech Company

Global UC-MSK Engine

SENTRIX Governance

Multi-Pathway Delivery Systems

40+ SKU Ecosystem





Subscription Revenue Engine

36-Month IPO Roadmap

2. Executive Summary


One slide, one message:

King Stem Cell is a scalable biologics platform with commercial traction and a clear path to IPO.

-  UC-MSC biologics engine (USA)
-  SENTRIX integrity & governance system
-  Multi-pathway delivery tech (sublingual, microneedle, transdermal)
-  40+ SKU product ecosystem



36-month IPO roadmap
targeting US\$100M+ market cap

-  Global subscription platform

3. The Problem

Biologics delivery is inefficient, unstable, and expensive.

- Cell-based biologics lose potency during transport
- No global chain-of-custody standard
- Delivery routes are invasive or low-bioavailability
- Consumer biologics lack GMP-grade integrity
- Clinics face inconsistent quality and regulatory risk





KING STEM CELL
HEALTHIER HAPPIER YOU


4. Our Solution: The King Stem Cell Platform

A three-pillar integrated biologics engine:



UC-MSK Biologics Engine

GMP validated, high
potency, scalable



SENTRIX Integrity System

Global governance,
traceability, audit trail




Delivery-Tech Architecture

Sublingual, microneedle,
transdermal

UC-MSC Biologics Engine

Upstream biologics production — USA



- ✓ **Xeno-free, FBS-free, DMSO-free**
Pure. Safe. Clinically relevant.
- ✓ **60–70 L/month CM capacity**
→ scaling to 150 L
Built for demand. Designed for scale.
- ✓ **Proprietary donor optimization**
Maximum potency. Consistent outcomes.
- ✓ **High-potency secretome**
Rich in growth factors, cytokines,
and regenerative signals.
- ✓ **GMP-validated, export-ready**
cGMP compliant. Global standards.
- ✓ **No foreign stem cell culture**
100% human-derived. Ethical. Compliant.



PRODUCED IN THE USA
QUALITY. INTEGRITY. TRUST.



Consistent Cell Quality
Rigorous selection and expansion standards.



Controlled Process
Closed system, low variability, high reproducibility.



Potent Secretome
Clinically relevant factors for repair and regeneration.



Safety First
Endotoxin-tested, mycoplasma-free, sterility assured.



Global Ready
Export-ready for regulated markets.



Science-Driven. Potency-Focused. GMP-Validated. Built for Global Impact.
The foundation of everything we deliver.

6. Pillar 2: SENTRIX Integrity System

Biologics governance, chain-of-custody, and compliance

- Real-time viability monitoring
- Anti-tamper governance
- Cryopreservation + thaw integrity
- Cross-border compliance
- Blockchain traceability
- Institutional-grade audit trail

7. Pillar 3: Delivery-Tech Architecture

Three high-performance delivery systems



Sublingual Soft-Press

- 92% bioavailability
- T_{max} 8–12 minutes
- 24-month stability



Dissolving Microneedle Patches

- 85% delivery efficiency
- Zero sharp waste
- 18-month stability



Transdermal Diffusion Systems

- 24-hour zero-order release
- 36-month stability

8. PILLAR 4

Product Ecosystem: 40+ SKUs

Multi-domain commercial architecture



Biologics-infused
cosmetics



Microneedle
patches



Sublingual
soft-press



Hair & scalp



Body &
transdermal



Clinic-grade
pipeline



40+ SKUs. One integrated ecosystem. Infinite impact.

SLIDE 9 — MARKET OPPORTUNITY: TAM • SAM • SOM

TAM — Total Addressable Market

Global Regenerative Medicine + Advanced Biologics & Precision Delivery Platforms

\$55 Billion (2026) 

Projected \$180–250 Billion by 2034 at 18–22% CAGR



SAM — Serviceable Addressable Market

MSC-derived Secretome/Exosome Therapeutics + Premium Regenerative Consumer Biologics (Skincare, Hair & Scalp, Body) + Multi-Pathway Delivery Systems

\$5.5–6.5 Billion (2026) 

Projected \$20–28 Billion by 2032–2033 at 22–25% CAGR



SOM — Serviceable Obtainable Market

Premium Consumer Wellness Subscription (40+ SKUs via SENTRIX integrity) + Early Clinical Biologics Pipeline (priority US/Asia/EU markets)

\$400–700 Million

realistic capture in 36–48 months

(Supports Phase 2 revenue target of \$32M+ and provides clear runway to IPO-scale valuation)

SOM captured 



Strategic Insight

- High-volume, high-margin recurring consumer wellness (skincare, hair/scalp, body)
- High-value clinical biologics with SENTRIX-enabled integrity and multi-pathway delivery

Competitive Landscape: The Only Integrated Stem Cell Platform

King Stem Cell®

The Only Platform Combining
All Five Pillars

GMP UC-MSC Engine

Fully scalable, clinical-grade
allogeneic MSC manufacturing
under FDA/EMA/PMDA
compliance



Global Governance System

Unified quality, ethics
& regulatory framework
across 14 jurisdictions

Multi-Pathway Delivery Tech

Proprietary cryopreserved
formulation + targeted
delivery systems

**KING STEM CELL
- UNIQUE
INTEGRATION**

Subscription Revenue Engine

Recurring high-margin
platform contracts with
clinics & research
networks

40+ SKU Commercial Ecosystem

Approved & commercialized
products across ortho, neuro,
autoimmune, and aesthetics

Competitive Landscape Matrix

Competitor	GMP UC-MSC	Global Governance	Multi-Pathway	40+ SKU	Subscription
StemCellCo	✓	✗	Partial	12	✗
RegenBio	✗	Partial	✓	18	✗
CellThera	✓	✗	✗	9	Partial
Others	✗	✗	✗	✗	✗
King Stem Cell	✓	✓	✓	✓	✓

REVENUE MODEL

Subscription Platform




Recurring Revenue




SaaS access • Analytics dashboard • Telehealth portal



Product Ecosystem



40+ SKUs



Direct-to-consumer + professional channels

Clinic-Grade Biologics



B2B



\$3.2M^{YTD}
Contract value: \$450K avg.

- ✓ Dermal biologics
- ✓ PRP kits
- ✓ Allograft matrix

B2B Contracts
42 active accounts

Diversified Revenue Streams

SUBSCRIPTION PLATFORM



8-WEEK RELEASE CYCLE

Structured and seamless delivery schedules.



3-TIER SUBSCRIPTION MODEL

Flexible plans tailored to individual patient needs.



MULTI-REGION FULFILMENT

US, UK/EU, Asia
Global logistics for rapid, reliable access.



HIGH RETENTION DRIVEN BY BIOLOGICS PERFORMANCE

Clinically proven outcomes ensure continued patient engagement.



PREDICTABLE RECURRING REVENUE

Stable, sustainable income streams for continuous growth.

Traction & Metrics

ARR Growth

85%



Subscriber Count

10,000+



Retention Rate

92%



CAC / LTV

1:3.5



Gross Margin

78%



SKU Velocity

500/mo



Clinic Partnerships: 50+




IP & TRADEMARK FORTRESS

KING STEM CELL™

HEALTHIER HAPPIER YOU

(US, UK, EU)
Vitacerebrum™
Timeless Aura™
SENTRIX™
(in progress)



Patent families

- Stem Cell Isolation
- Gene Editing Vectors
- Cellular Rejuvenation

Global multi-class protection

15. Manufacturing Scale-Up Roadmap

Q3 2025 → Q2 2028



New purification suites
(Cambridge, Frankfurt)



Automation + QC systems
PAT integration



**Expanded delivery-
tech lines**

Regulatory Pathway

US, UK/EU, Asia frameworks

Navigating global standards for advanced therapy medicinal products.

Device classifications

Adhering to strict risk-based medical device regulations.

Compliance milestones

Structured phases for clinical validation and quality assurance.

SENTRIX governance advantage

Proprietary ethical oversight and superior quality management.


KING STEM CELL
HEALTHIER HAPPIER YOU

Team & Advisors


- ✓ Biologics manufacturing
- ✓ Regulatory
- ✓ Delivery-tech
- ✓ Subscription commerce
- ✓ Capital markets / IPO readiness

18. Financial Projections


36-Month Revenue Model



Gross Margin Expansion



Capex vs Output Comparison



Subscription Growth Curve




EBITDA Trajectory




19. Capital Requirements



Three-Stage Capital Architecture



20. USE OF FUNDS





36-Month IPO Roadmap

Phase 1: Platform Acceleration

Optimizing cellular platform and expanding clinical trial pipelines.

Months 1-12

Phase 2: Institutional Capital & Global Scale

Securing strategic partnerships, scaling manufacturing, and raising Series funding.

Months 13-24

Phase 3: Pre-IPO Structuring & Nasdaq Execution

Finalizing regulatory compliance, corporate governance, and executing the Nasdaq listing.

Months 25-36



KING STEM CELL
HEALTHIER HAPPIER YOU

A scalable biologics platform ready for global expansion.

Contact • Data Room • Next Steps

